Ferrer and colleagues [11] also supported this finding and showed that a combined analysis of B-cell activating factor and sAPRIL levels may be more useful to predict disease progression in CLL patients. The gene discussed is TNFSF13B; the disease is B-cell chronic lymphocytic leukemia.